Oxurion NV (XBRU:OXUR) Debt-to-Asset : 1.88 (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Oxurion NV Debt-to-Asset?

Oxurion NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €12.22 Mil. Oxurion NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.12 Mil. Oxurion NV's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was €6.55 Mil. Oxurion NV's debt to asset for the quarter that ended in Dec. 2023 was 1.88.

Oxurion NV Debt-to-Asset Historical Data

The historical data trend for Oxurion NV's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxurion NV Debt-to-Asset Chart

Oxurion NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.03

0.64

0.67

1.88

Oxurion NV Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.64	0.63	0.67	0.93	1.88

Competitive Comparison of Oxurion NV's Debt-to-Asset

For the Biotechnology subindustry, Oxurion NV's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxurion NV's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxurion NV's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Oxurion NV's Debt-to-Asset falls into.

Oxurion NV Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Oxurion NV's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(12.217	+	0.117)	/	6.55
	=	1.88

Oxurion NV's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(12.217	+	0.117)	/	6.55
	=	1.88

Oxurion NV (XBRU:OXUR) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Oxurion NV Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Oxurion NV's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxurion NV (XBRU:OXUR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxurion NV (XBRU:OXUR) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

TG4:Germany

Address

Gaston Geenslaan 1, Leuven, BEL, B-3001

Website

https://www.oxurion.com

Oxurion NV is a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME). The Group's research and development facilities are located in Belgium .The Company is engaged in the development of drugs to treat back-of-the-eye diseases, more specifically, ophthalmologic pharmaceuticals to treat vascular retinal disorders, specifically DME.

Oxurion NV (XBRU:OXUR) Headlines

No Headlines